Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 2.80% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-04-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2019-04-10
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 2.00%, a 33.33% increase year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 1.50%, a 2.04% increase year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.47%, a 13.53% decline year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-03-31 was 1.70%, a 120.78% increase year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.80%, a 40.00% increase from fiscal 2017.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 2.00%, a 33.33% increase from fiscal 2016.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 1.50%, a 11.76% decline from fiscal 2015.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 1.70%, a 9.68% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 2.80% 10-K · filed 2019-04-10 | |||||||
| 2018-09-30 | 2.80% 10-Q · filed 2018-11-14 | |||||||
| 2018-06-30 | 2.80% 10-Q · filed 2018-08-14 | |||||||
| 2017-12-31 | 2.00% 10-K · filed 2019-04-10 | |||||||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-14 | |||||||
| 2017-06-30 | 2.00% 10-Q · filed 2018-08-14 | |||||||
| 2017-03-31 | 2.00% 10-Q · filed 2018-05-14 | |||||||
| 2016-12-31 | 1.50% 10-K · filed 2018-04-17 | |||||||
| 2016-09-30 | 1.50% 10-Q · filed 2017-11-14 | |||||||
| 2016-06-30 | 1.50% 10-Q · filed 2017-08-02 | |||||||
| 2016-03-31 | 1.50% 10-Q · filed 2017-05-08 | 1.53% 10-Q · filed 2016-05-06 | ||||||
| 2015-12-31 | 1.70% 10-K · filed 2017-03-30 | 1.71% 10-K · filed 2016-03-25 | ||||||
| 2015-09-30 | 1.70% 10-Q · filed 2016-11-14 | 1.71% 10-Q · filed 2015-11-12 | ||||||
| 2015-06-30 | 1.70% 10-Q · filed 2016-08-02 | 1.69% 10-Q · filed 2015-08-06 | ||||||
| 2015-03-31 | 1.47% 10-Q · filed 2016-05-06 | |||||||
| 2014-12-31 | 1.55% 10-K · filed 2016-03-25 | |||||||
| 2014-09-30 | 1.57% 10-Q · filed 2015-11-12 | |||||||
| 2014-06-30 | 1.56% 10-Q · filed 2015-08-06 | |||||||
| 2014-03-31 | 1.70% 10-Q · filed 2014-05-08 | |||||||
| 2013-12-31 | 0.95% 10-K · filed 2015-03-30 | |||||||
| 2013-09-30 | 0.95% 10-Q · filed 2013-11-13 | |||||||
| 2013-06-30 | 0.77% 10-Q/A · filed 2013-10-18 | |||||||
| 2013-03-31 | 0.77% 10-Q · filed 2013-05-09 | |||||||
| 2012-12-31 | 0.85% 10-K · filed 2015-03-30 | |||||||
| 2012-09-30 | 0.85% 10-Q · filed 2012-11-09 | |||||||
| 2012-06-30 | 1.04% 10-Q · filed 2012-08-13 | |||||||
| 2011-12-31 | 0.26% 10-K · filed 2014-03-20 | |||||||
| 2010-12-31 | 1.83% 10-K · filed 2013-03-15 |